Moderate riskFDA DrugClass II

Major Pharmaceuticals levothyroxine tablets recalled for subpotency

Major Pharmaceuticals is recalling levothyroxine sodium 50 mcg tablets (lot N02200, expiration 10/2026) because they do not contain the full labeled dose. Levothyroxine is a thyroid hormone replacement medication, and a subpotent tablet may not provide the intended therapeutic effect for patients who depend on consistent dosing.

From the FDA notice · Read the official notice ↗

What to do

  1. Check if you have levothyroxine sodium 50 mcg tablets from Major Pharmaceuticals with lot number N02200.
  2. Do not stop taking your levothyroxine without speaking to your doctor.
  3. Contact your pharmacist or doctor to confirm whether your supply is affected and discuss next steps.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Levothyroxine Sodium Tablets, USP, 50 mcg (0.050 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6950-61
Sold in
Nationwide
Made for
Adults (0 months and older)

This recall covers 12 products — see all of them.

Details

Units affected
N/A
Illnesses reported
None reported
Manufactured in
7000 Cardinal Pl, N/A, Dublin, OH, United States
Classification
Class II
Recall number
D-0701-2026

In the FDA's words

Description
Levothyroxine Sodium Tablets, USP, 50 mcg (0.050 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6950-61 Subpotent Drug Lot #: N02200, Exp. Date 10/2026 Distribution: Nationwide in the USA. Affected quantity: N/A
Hazard
Subpotent Drug

12 products in this recall

The agency lists each product separately. Check every one you might have.

Related topics

PotencyDrugsSold nationwideMore from FDA Drug